Downloading...
Download

Covidstocks

Covid & Vaccine Related Novavax Long Play in the cardsHi guys! So lately theres been some buzz on a particular variant, increased cases of hospitalizations and government backing. At risk population that require vaccinations/ boosters will always exist. Therefore, i believe this fact along with various technical analysis findings can make companies such as Biontech, Moderna and even not as famous Novavax potential plays. (Look below for my analysis on Biontech) Jumping right in. This is a technical analysis on Novavax (NVAX) on the 3 day timeframe. Zoomed in we can see that we have a GOLDEN CROSS. Between the: 21 EMA 50 SMA Being on the 3 Day its ALOT more Powerful than having it on 1 Day and it may influence the larger timeframes. Which is what we want. We have also maintained SUPPORT on both Moving Average. (21 EMA and 50 SMA) This is a great sign, if we continue like how we are with our current candle during the close that would further confirm Support and a bullish case in my opinion. This 3 day candle will close on the 8th of September. Pay attention to how big the body of candle gets on the close. With this i would like Volume to start to pick up especially if and when we get to the "flat trendline". Another important development to notice is the Ascending Triangle. This can be giving us evidence we are in the process of BOTTOMING out. Watch for the breakout ABOVE the Flatline. This with confirmation of Support on flatline would be a Major Area to take Long Positions. I would ADVISE AGAINST buying inside the triangle. But Belowthe Ascending Support Line would be an area for Stop losses. Watch also how the MACD acts. If we continue in Green and the Blue/Orange lines make it ABOVE 0 level. We will be off to the races, as it would be the necessary catalyst that provides momentum to have the triangle play out. __________________________________________________________________________________ Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again. Stay tuned for more updates on NVAX in the near future. If you have any questions, do reach out. Thank you again. DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
NASDAQ:NVAXLong
by SafofAllTrades
2
MODERNA has most likely bottomedModerna Inc (MRNA), a much discussed stock over the previous years, is having a +8% day, a very encouraging since following the rejection on the 1D MA50 (blue trend-line) three days ago. What's more interesting is that we have seen almost the same pattern in the stock's all time lows in 2019. As you see, the price since September has been on Lower Lows while the 1D RSI has been on Higher Lows, indicating a Bullish Divergence that is often seen on market bottoms before the price reverses. The very same Bullish Divergence was spotted from June 25 2019 until August 07 2019. It was also a remarkable 1D candle of +20% back then that signaled the sentiment shift. The price confirmed those bias when it broke above the 1D MA50. The break of the 1D MA200 (orange trend-line) a few days later opened the way for an incredible two year rise that was of course dominated by the COVID fundamentals mostly. It is worth noting that at the moment the 1D MA200 is too close to the 1D MA50 as opposed to 2019, so best to have our mark on the 1W MA100 (green trend-line) which has rejected both of 2022 uptrends in March 21 and August 04. It is exactly now where the 200.00 Resistance is (formed by the August 04 High). Also notice that the 1W MA200 (red trend-line) has made its appearance in October for the first time in history and provided the necessary Support for the early October push. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:MRNALong
by TradingShot
HGEN in EU Commission 10 Most Promising Treatments for COVID-19!European Commission’s independent experts selected Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19! CEO of Humanigen said today: "We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19". In the same list you can see Pfizer, Roche, Astra Zeneca and Eli Lilly! Humanigen is the smallest company. Institutions loaded big on this dip of Humanigen, Inc. (HGEN), 132Mil in the last quarter! On 8/23/2021 Morgan Stanley reported an increased ownership in HGEN by +1,884.6%! Biggest shareholder is Blackrock with 3,037,693 shares worth $52.80Mil, which increased its position by +283.5% for a total ownership of 5.141% of Humanigen. So Blackrock paid an average of 17.3usd per share! The price of the stock is now 6.60usd! H.C. Wainwright’s Joseph Pantginis rates HGEN a Buy along with a $28 price target and said the market overreacted on that selloff. My price target is the 16.3usd resistance!
HLong
by TopgOptions
11
BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study. BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc. "With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data." James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies." The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
CSE:BIOVLong
by agstockpicks
KNR -- Oversold; Double Bottom at .89. On watch for a bounce.KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open market. Share buyback program is in effect. Bullish MACD divergence on the chart.
NEO:KNRLong
by agstockpicks
1
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.: - 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk. - Bottom of Risk Range: - S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io - Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com - Good short squeeze material. - Non Optionable. Bought the shares $16.69 Expect share dilution $40-$50 GLHF - DPT
NASDAQ:CMMBLong
by UnknownUnicorn1043646
3
Dollar General/ DG GREAT BUY Surprisingly enough this company is stellar when you look at the financials. Its Cash Cycle is under 30 days with absolutely NO ACCOUNTS RECIEVABLE!!! its been growing its revenue around 10% each year, management has been buying back shares to increase shareholder equity, its dividends are squat :( , but they are gunning for Five and Below/ FIVE s market by opening POP Shelfs in the 'Burbs. If the POP Shelfs are able to take hold then I could see this company keeping par with its 10% revenue growth rate for the next 10 years. For the past decade the GPM has not dipped below 30%. the Return on Equity (for the value investors like myself) has been steadily growing with the last years being 25.5% with a 10 year average of 20%. And with COVID-19 still keeping people out of work and unemployment moderate to high I can see more households stretching the dollar which will grow this company's Revenue. As the families effected will be looking for the bargain stores to save their capital. The Company has ZERO short term debt, but they have no treasury shares. :( so, they have no equity out of the market and i think this particular reason is why i think its more of a "B+" investment rather than a A+ investment. If you're a conservative investor the D/E Ratio for the past year was .43, so that's not bad! with only 4% of their operating income going toward paying off interest on long term debt as compared to the moderate 15%. :) so when they buy their shares back its possible they might be retiring them. the Current Ratio has been a strong 1.5-1.7 for the past decade with a few exceptions, and their retained earnings pool has been steadily growing. Currently its trading under value with a fair market value of 196.xx with Ben Grahams formula putting it around 294.xx. I would love to see the price drop below 185.xx before buying so that way one can maximize their return on investment. If you're a growth investor or value investor this is a great company a solid B+ or A- to build a portfolio on. I would love to see this ABCD pattern complete as a great entry.
NYSE:DGLong
by ARegularGuy
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. finance.yahoo.com
A
by AlenCiken
1
ArcticZymes $AZT Q3 2020 reportHighlights for Q3 2020 • Annual group sales exceed 100 MNOK for the first time • Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million) • ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million) • Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million) • Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health • The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million) • Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
OSL:AZT
by savepiginvest
1